SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (7238)10/24/2002 8:47:48 PM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
WE,

MLNM have two patent applications directed to proteosome cleavage of the IkappaBalpha and kinase antagonist:

20020086407 23484, a novel human ubiquitin protease
20020151553 Chemokine receptor antagonists and methods of use therefor

They bought 341, so it is up to first license contract and what was license to determine do they have intellectual right for proteosome enzyme. This will be under different application assignee search.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News